organization · Reporting owner
Opaleye Management Inc.
Disclosed activity across 11 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alpha Cognition Inc.ACOG · Entity 6339 | 10% owner | October 01, 2026 | October 03, 2026 |
| CODEXIS, INC.CDXS · Entity 6428 | 10% owner | November 26, 2025 | December 15, 2025 |
| Grace Therapeutics, Inc.GRCE · Entity 7266 | 10% owner | October 08, 2026 | October 13, 2026 |
| HARROW, INC.HROW · Entity 4740 | 10% owner | March 03, 2026 | March 05, 2026 |
| Protara Therapeutics, Inc.TARA · Entity 6203 | 10% owner | September 11, 2024 | September 13, 2024 |
| Sol-Gel Technologies Ltd.SLGL · Entity 1558 | 10% owner | September 10, 2026 | September 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alpha Cognition Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, no par valueSEC Table I · non-derivative | IndirectBy Opaleye, L.P. | 3,222,954 |
Reported balance
After 2026-10-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-10-01 · Purchase · Acquired 19,050 · Balance 3,222,954 F3: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.645 to $8.70. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range. F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. F4: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock, no par valueSEC Table I · non-derivative | IndirectBy Managed Account | 100,000 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 100,000 F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Managed Account. F4: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Managed Account.
F3: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.645 to $8.70. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.
F4: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.
CODEXIS, INC.
Report date November 26, 2025 · Filed December 15, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectBy Opaleye, L.P. | 10,305,000 |
Reported balance
After 2025-11-26 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-11-26 · Sale · Disposed 148,318 · Balance 10,305,000 F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.7316 - $1.75699 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F6: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectBy Opaleye, L.P. | 10,200,000 |
Reported balance
After 2025-11-28 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2025-11-28 · Sale · Disposed 105,000 · Balance 10,200,000 F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 - $1.7715 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F6: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectBy Opaleye, L.P. | 9,955,000 |
Reported balance
After 2025-12-01 transaction · row 5
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 5 · 2025-12-01 · Sale · Disposed 245,000 · Balance 9,955,000 F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. F5: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.65 - $1.7101 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F6: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectBy Managed Account | 191,012 |
Reported balance
After 2025-11-26 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2025-11-26 · Sale · Disposed 5,000 · Balance 191,012 F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.7316 - $1.75699 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F6: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectBy Managed Account | 188,522 |
Reported balance
After 2025-11-28 transaction · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · 2025-11-28 · Sale · Disposed 2,490 · Balance 188,522 F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 - $1.7715 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F6: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectBy Managed Account | 179,989 |
Reported balance
After 2025-12-01 transaction · row 6
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 6 · 2025-12-01 · Sale · Disposed 8,533 · Balance 179,989 F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. F5: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.65 - $1.7101 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F6: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.7316 - $1.75699 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 - $1.7715 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
F5: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.65 - $1.7101 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
F6: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Grace Therapeutics, Inc.
Report date October 08, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectBy Opaleye, L.P. | 2,873,289 |
Last balance in matching sequence
After 2026-10-12 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-10-08 · Purchase · Acquired 2,077 · Balance 2,860,734 F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund. F3: Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 2 · 2026-10-09 · Purchase · Acquired 5,340 · Balance 2,866,074 F2: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.03 to $2.05. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range. F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund. F3: Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 3 · 2026-10-12 · Purchase · Acquired 7,215 · Balance 2,873,289 F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund. F3: Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund.
F2: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.03 to $2.05. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.
F3: Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.
HARROW, INC.
Report date March 03, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectBy Opaleye, L.P. | 3,622,000 |
Last balance in matching sequence
After 2026-03-04 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-03-03 · Sale · Disposed 59,000 · Balance 3,756,000 F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.50 to $40.66. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range. F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. F5: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 3 · 2026-03-04 · Sale · Disposed 134,000 · Balance 3,622,000 F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.12 to $40.50. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range. F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. F5: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectBy Managed Account | 59,428 |
Last balance in matching sequence
After 2026-03-04 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2026-03-03 · Sale · Disposed 1,309 · Balance 63,691 F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.50 to $40.66. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range. F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. F5: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 4 · 2026-03-04 · Sale · Disposed 4,263 · Balance 59,428 F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.12 to $40.50. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range. F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. F5: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.50 to $40.66. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.12 to $40.50. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
F5: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Protara Therapeutics, Inc.
Report date September 11, 2024 · Filed September 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectBy Opaleye, L.P. | 1,944,134 |
Last balance in matching sequence
After 2024-09-12 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-09-11 · Sale · Disposed 31,000 · Balance 2,063,935 F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70-$1.74 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Row 3 · 2024-09-12 · Sale · Disposed 119,801 · Balance 1,944,134 F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70-$1.75 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectBy Managed account | 45,000 |
Last balance in matching sequence
After 2024-09-12 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2024-09-11 · Sale · Disposed 1,600 · Balance 51,500 F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70-$1.74 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. Row 4 · 2024-09-12 · Sale · Disposed 6,500 · Balance 45,000 F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70-$1.75 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70-$1.74 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70-$1.75 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
Sol-Gel Technologies Ltd.
Report date September 10, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value NIS 1.00 per shareSEC Table I · non-derivative | IndirectBy Opaleye, L.P. | 540,000 |
Last balance in matching sequence
After 2026-09-11 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-09-10 · Purchase · Acquired 1,631 · Balance 538,507 F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund. F3: Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 2 · 2026-09-11 · Purchase · Acquired 1,493 · Balance 540,000 F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund. F3: Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Ordinary Shares, par value NIS 1.00 per shareSEC Table I · non-derivative | IndirectBy Managed Account | 15,000 |
Reported balance
Holding disclosure · report date 2026-09-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 15,000 F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Managed Account. F3: Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund.
F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Managed Account.
F3: Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Past disclosures · reporting ended (5)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Eton Pharmaceuticals, Inc.
Report date July 14, 2026 · Filed July 17, 2026 · Amendment
Section 16 reporting ended · disclosed 2026-07-17. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectBy Opaleye, L.P. | 2,665,000 |
Reported balance
After 2026-07-14 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-07-14 · Sale · Disposed 15,000 · Balance 2,665,000 F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.0152 to $37.9148 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund. F4: Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectBy Managed Account | 40,000 |
Reported balance
After 2026-07-14 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2026-07-14 · Sale · Disposed 13,315 · Balance 40,000 F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.0152 to $37.9148 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Managed Account. F4: Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund.
F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Managed Account.
F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.0152 to $37.9148 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
F4: Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.
OCULAR THERAPEUTIX, INC
Report date April 03, 2020 · Filed April 03, 2020
Section 16 reporting ended · disclosed 2020-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectBy Opaleye, L.P. | 4,915,000 |
Reported balance
Holding disclosure · report date 2020-04-03 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 4,915,000 F1: No transactions are being reported in connection with this Form 4. The stock ownership listed was previously reported on a Form 3, Form 4 and Schedule 13G/A filed with the SEC. Based on the total number of shares of common stock reported issued and outstanding by the Issuer in its annual report on Form 10-K, filed with the SEC on March 12, 2020, the Reporting Person no longer owns in excess of 10% of the Issuer's common stock, and this Form 4 is being filed solely to reflect that the Reporting Person is no longer subject to Section 16 reporting obligations in connection with its holdings of the Issuer. F2: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. ("Opaleye") may be deemed to beneficially own the securities owned directly by the Fund. |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectBy Managed Account | 207,500 |
Reported balance
Holding disclosure · report date 2020-04-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 207,500 F1: No transactions are being reported in connection with this Form 4. The stock ownership listed was previously reported on a Form 3, Form 4 and Schedule 13G/A filed with the SEC. Based on the total number of shares of common stock reported issued and outstanding by the Issuer in its annual report on Form 10-K, filed with the SEC on March 12, 2020, the Reporting Person no longer owns in excess of 10% of the Issuer's common stock, and this Form 4 is being filed solely to reflect that the Reporting Person is no longer subject to Section 16 reporting obligations in connection with its holdings of the Issuer. F3: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. |
| American-style call optionSEC Table II · derivative / convertible security · Conversion / exercise price $7.50 · Expires 2020-06-19 | IndirectBy Opaleye, L.P. | 1,000 |
Reported balance
Holding disclosure · report date 2020-04-03 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 1,000 F1: No transactions are being reported in connection with this Form 4. The stock ownership listed was previously reported on a Form 3, Form 4 and Schedule 13G/A filed with the SEC. Based on the total number of shares of common stock reported issued and outstanding by the Issuer in its annual report on Form 10-K, filed with the SEC on March 12, 2020, the Reporting Person no longer owns in excess of 10% of the Issuer's common stock, and this Form 4 is being filed solely to reflect that the Reporting Person is no longer subject to Section 16 reporting obligations in connection with its holdings of the Issuer. F2: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. ("Opaleye") may be deemed to beneficially own the securities owned directly by the Fund. |
Filing footnotes · ownership attribution and instrument terms
F1: No transactions are being reported in connection with this Form 4. The stock ownership listed was previously reported on a Form 3, Form 4 and Schedule 13G/A filed with the SEC. Based on the total number of shares of common stock reported issued and outstanding by the Issuer in its annual report on Form 10-K, filed with the SEC on March 12, 2020, the Reporting Person no longer owns in excess of 10% of the Issuer's common stock, and this Form 4 is being filed solely to reflect that the Reporting Person is no longer subject to Section 16 reporting obligations in connection with its holdings of the Issuer.
F2: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. ("Opaleye") may be deemed to beneficially own the securities owned directly by the Fund.
F3: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
SANUWAVE Health, Inc.
Report date April 30, 2026 · Filed May 04, 2026
Section 16 reporting ended · disclosed 2026-05-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectBy Opaleye, L.P. | 853,569 |
Last balance in matching sequence
After 2026-05-01 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-04-30 · Sale · Disposed 24,000 · Balance 863,650 F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.10-$16.775 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. F5: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 3 · 2026-05-01 · Sale · Disposed 10,081 · Balance 853,569 F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00-$16.28 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. F5: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectBy Managed account | 5,000 |
Last balance in matching sequence
After 2026-05-01 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2026-04-30 · Sale · Disposed 1,000 · Balance 5,500 F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.10-$16.775 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. F5: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 4 · 2026-05-01 · Sale · Disposed 500 · Balance 5,000 F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00-$16.28 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. F5: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.10-$16.775 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00-$16.28 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
F5: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.
TELA Bio, Inc.
Report date April 20, 2023 · Filed April 20, 2023
Section 16 reporting ended · disclosed 2023-04-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectBy Managed Account | 124,813 |
Reported balance
Holding disclosure · report date 2023-04-20 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 124,813 F1: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to own the securities owned directly by the Managed Account. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectBy Opaleye, L.P. | 1,948,000 |
Reported balance
Holding disclosure · report date 2023-04-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,948,000 F2: Represents securities directly owned by Opaleye, L.P. ("the fund"). As the investment manager of the Fund, Opaleye Management may be deemed to own the securities owned directly by the Fund. |
Filing footnotes · ownership attribution and instrument terms
F1: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to own the securities owned directly by the Managed Account.
F2: Represents securities directly owned by Opaleye, L.P. ("the fund"). As the investment manager of the Fund, Opaleye Management may be deemed to own the securities owned directly by the Fund.
Tracon Pharmaceuticals, Inc.
Report date November 10, 2023 · Filed November 14, 2023
Section 16 reporting ended · disclosed 2023-11-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectBy Opaleye, L.P. | 0 |
Reported balance
After 2023-11-10 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-11-10 · Sale · Disposed 4,324,008 · Balance 0 F3: This transaction was executed in multiple trades at prices ranging from $0.21 to $0.375; the price reported above reflects the weighted average purchase price. The reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased. F1: Represents securities owned directly by Opaleye, L.P. (The "Fund"). As the investment manager of the Fund. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectBy Managed account | 0 |
Reported balance
After 2023-11-10 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-11-10 · Sale · Disposed 440,000 · Balance 0 F3: This transaction was executed in multiple trades at prices ranging from $0.21 to $0.375; the price reported above reflects the weighted average purchase price. The reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased. F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to own the securities owned directly by the Managed Account beneficially. |
| Prefunded WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2030-08-27 | IndirectBy Opaleye,L.P. | 1,667,974 |
Reported balance
Holding disclosure · report date 2023-11-10 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 1,667,974 F4: The warrants may not be exercised to the extent that such exercise would cause the reporting person and its affiliates to beneficially own more than 19.99% of the Issuer's then outstanding common stock. F1: Represents securities owned directly by Opaleye, L.P. (The "Fund"). As the investment manager of the Fund. |
| Prefunded WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2030-08-31 | IndirectBy Opaleye,L.P. | 1,358,993 |
Reported balance
Holding disclosure · report date 2023-11-10 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 1,358,993 F4: The warrants may not be exercised to the extent that such exercise would cause the reporting person and its affiliates to beneficially own more than 19.99% of the Issuer's then outstanding common stock. F1: Represents securities owned directly by Opaleye, L.P. (The "Fund"). As the investment manager of the Fund. |
| Prefunded WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2032-06-21 | IndirectBy Opaleye, L.P. | 2,205,018 |
Reported balance
Holding disclosure · report date 2023-11-10 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 2,205,018 F4: The warrants may not be exercised to the extent that such exercise would cause the reporting person and its affiliates to beneficially own more than 19.99% of the Issuer's then outstanding common stock. F1: Represents securities owned directly by Opaleye, L.P. (The "Fund"). As the investment manager of the Fund. |
| Prefunded WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2033-03-09 | IndirectBy Opaleye, L.P. | 2,013,999 |
Reported balance
Holding disclosure · report date 2023-11-10 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 2,013,999 F4: The warrants may not be exercised to the extent that such exercise would cause the reporting person and its affiliates to beneficially own more than 19.99% of the Issuer's then outstanding common stock. F1: Represents securities owned directly by Opaleye, L.P. (The "Fund"). As the investment manager of the Fund. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents securities owned directly by Opaleye, L.P. (The "Fund"). As the investment manager of the Fund.
F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to own the securities owned directly by the Managed Account beneficially.
F3: This transaction was executed in multiple trades at prices ranging from $0.21 to $0.375; the price reported above reflects the weighted average purchase price. The reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased.
F4: The warrants may not be exercised to the extent that such exercise would cause the reporting person and its affiliates to beneficially own more than 19.99% of the Issuer's then outstanding common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2024 Filed Sep 10, 2024 23:11 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 24,000 | $1.77 | $42,456.00 |
DisclosureSEC source: 0001493152-24-035684 · ownership.xml · nonDerivative · entry 3 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 2,094,935 F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69-$1.81 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| September 10, 2024 Filed Sep 12, 2024 23:31 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | PurchaseCommon Stock, par value $0.001 per share | 7,500 | $4.65 | $34,875.00 |
DisclosureSEC source: 0001493152-24-036104 · ownership.xml · nonDerivative · entry 2 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Managed account Disclosed balance after: 70,000 F2 · ownership.nature: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. F3 · ownership.nature: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| September 10, 2024 Filed Sep 12, 2024 23:31 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | PurchaseCommon Stock, par value $0.001 per share | 50,000 | $4.65 | $232,500.00 |
DisclosureSEC source: 0001493152-24-036104 · ownership.xml · nonDerivative · entry 1 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 2,660,000 F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. F3 · ownership.nature: Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| September 09, 2024 Filed Sep 10, 2024 23:11 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 1,900 | $1.89 | $3,599.93 |
DisclosureSEC source: 0001493152-24-035684 · ownership.xml · nonDerivative · entry 2 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Managed account Disclosed balance after: 54,600 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84-$1.9566 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F2 · ownership.nature: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. Read SEC document |
| September 09, 2024 Filed Sep 10, 2024 23:11 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 34,592 | $1.89 | $65,541.46 |
DisclosureSEC source: 0001493152-24-035684 · ownership.xml · nonDerivative · entry 1 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 2,118,935 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84-$1.9566 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 20:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 3,500 | $2.44 | $8,546.65 |
DisclosureSEC source: 0001493152-24-028330 · ownership.xml · nonDerivative · entry 2 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Managed account Disclosed balance after: 56,500 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.4397-$2.5125 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F2 · ownership.nature: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 20:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 7,896 | $2.44 | $19,281.24 |
DisclosureSEC source: 0001493152-24-028330 · ownership.xml · nonDerivative · entry 1 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 2,153,527 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.4397-$2.5125 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| July 11, 2024 Filed Jul 11, 2024 23:56 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 15,000 | $2.40 | $36,051.00 |
DisclosureSEC source: 0001493152-24-027028 · ownership.xml · nonDerivative · entry 6 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Managed account Disclosed balance after: 60,000 F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.3688-$2.4602 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F2 · ownership.nature: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. Read SEC document |
| July 11, 2024 Filed Jul 11, 2024 23:56 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 32,993 | $2.40 | $79,295.38 |
DisclosureSEC source: 0001493152-24-027028 · ownership.xml · nonDerivative · entry 5 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 2,161,423 F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.3688-$2.4602 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| July 10, 2024 Filed Jul 11, 2024 23:56 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 5,000 | $2.31 | $11,540.00 |
DisclosureSEC source: 0001493152-24-027028 · ownership.xml · nonDerivative · entry 4 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Managed account Disclosed balance after: 75,000 F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.20-$2.313 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F2 · ownership.nature: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. Read SEC document |
| July 10, 2024 Filed Jul 11, 2024 23:56 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 13,061 | $2.31 | $30,144.79 |
DisclosureSEC source: 0001493152-24-027028 · ownership.xml · nonDerivative · entry 3 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 2,194,416 F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.20-$2.313 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 23:56 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 2,500 | $2.21 | $5,534.50 |
DisclosureSEC source: 0001493152-24-027028 · ownership.xml · nonDerivative · entry 2 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Managed account Disclosed balance after: 80,000 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.2128-$2.25 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F2 · ownership.nature: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 23:56 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 5,997 | $2.21 | $13,276.16 |
DisclosureSEC source: 0001493152-24-027028 · ownership.xml · nonDerivative · entry 1 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 2,207,477 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.2128-$2.25 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 18:00 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 2,500 | $2.12 | $5,308.25 |
DisclosureSEC source: 0001493152-24-026181 · ownership.xml · nonDerivative · entry 2 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Managed account Disclosed balance after: 87,500 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.1021-$2.1611 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F2 · ownership.nature: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 18:00 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 5,788 | $2.12 | $12,289.66 |
DisclosureSEC source: 0001493152-24-026181 · ownership.xml · nonDerivative · entry 1 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 2,213,474 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.1021-$2.1611 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| June 28, 2024 Filed Jun 28, 2024 22:45 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 5,000 | $2.07 | $10,374.00 |
DisclosureSEC source: 0001493152-24-025666 · ownership.xml · nonDerivative · entry 4 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Managed account Disclosed balance after: 85,000 F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.05-$2.26 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F2 · ownership.nature: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. Read SEC document |
| June 28, 2024 Filed Jun 28, 2024 22:45 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 12,994 | $2.07 | $26,959.95 |
DisclosureSEC source: 0001493152-24-025666 · ownership.xml · nonDerivative · entry 3 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 2,219,262 F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.05-$2.26 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| June 27, 2024 Filed Jun 28, 2024 22:45 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 12,471 | $2.26 | $28,160.77 |
DisclosureSEC source: 0001493152-24-025666 · ownership.xml · nonDerivative · entry 2 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Managed account Disclosed balance after: 90,000 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.10-$2.25 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F2 · ownership.nature: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. Read SEC document |
| June 27, 2024 Filed Jun 28, 2024 22:45 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 34,103 | $2.26 | $77,007.98 |
DisclosureSEC source: 0001493152-24-025666 · ownership.xml · nonDerivative · entry 1 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 2,232,256 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.10-$2.25 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 20:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 6,225 | $2.26 | $14,056.67 |
DisclosureSEC source: 0001493152-24-025428 · ownership.xml · nonDerivative · entry 2 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Managed account Disclosed balance after: 102,471 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25-$2.26 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F2 · ownership.nature: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 20:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 6,500 | $2.26 | $14,677.65 |
DisclosureSEC source: 0001493152-24-025428 · ownership.xml · nonDerivative · entry 1 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 2,266,359 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25-$2.26 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| May 31, 2024 Filed May 31, 2024 20:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 5,824 | $2.90 | $16,894.84 |
DisclosureSEC source: 0001493152-24-022195 · ownership.xml · nonDerivative · entry 2 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Managed account Disclosed balance after: 108,696 F3 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.9007-$2.9011 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F1 · ownership.nature: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. Read SEC document |
| May 30, 2024 Filed May 31, 2024 20:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 9,230 | $2.94 | $27,113.13 |
DisclosureSEC source: 0001493152-24-022195 · ownership.xml · nonDerivative · entry 1 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Managed account Disclosed balance after: 114,520 F2 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.90-$2.98 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F1 · ownership.nature: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. Read SEC document |
| May 22, 2024 Filed May 23, 2024 23:01 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 500 | $3.00 | $1,501.05 |
DisclosureSEC source: 0001493152-24-021230 · ownership.xml · nonDerivative · entry 4 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Managed account Disclosed balance after: 123,750 F4 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.00-$3.03 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F2 · ownership.nature: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. Read SEC document |
| May 22, 2024 Filed May 23, 2024 23:01 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 9,300 | $3.02 | $28,095.30 |
DisclosureSEC source: 0001493152-24-021230 · ownership.xml · nonDerivative · entry 3 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Managed account Disclosed balance after: 2,272,859 F4 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.00-$3.03 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F2 · ownership.nature: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. Read SEC document |
| May 21, 2024 Filed May 23, 2024 23:01 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 1,800 | $3.06 | $5,500.26 |
DisclosureSEC source: 0001493152-24-021230 · ownership.xml · nonDerivative · entry 2 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Managed account Disclosed balance after: 124,250 F3 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.01-$3.17 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F2 · ownership.nature: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. Read SEC document |
| May 21, 2024 Filed May 23, 2024 23:01 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 31,200 | $3.06 | $95,337.84 |
DisclosureSEC source: 0001493152-24-021230 · ownership.xml · nonDerivative · entry 1 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 2,282,159 F3 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.01-$3.17 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| May 17, 2024 Filed May 17, 2024 23:48 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 1,200 | $3.06 | $3,672.72 |
DisclosureSEC source: 0001493152-24-020507 · ownership.xml · nonDerivative · entry 4 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Managed account Disclosed balance after: 126,050 F4 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.00-$3.10 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F2 · ownership.nature: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. Read SEC document |
| May 17, 2024 Filed May 17, 2024 23:48 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 2,750 | $3.33 | $9,152.28 |
DisclosureSEC source: 0001493152-24-020507 · ownership.xml · nonDerivative · entry 3 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Managed account Disclosed balance after: 127,250 F3 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.01-$3.60 inclusive. The reporting person undertakes to provide,upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F2 · ownership.nature: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. Read SEC document |
| May 17, 2024 Filed May 17, 2024 23:48 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 19,685 | $3.06 | $60,247.91 |
DisclosureSEC source: 0001493152-24-020507 · ownership.xml · nonDerivative · entry 2 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 2,313,359 F4 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.00-$3.10 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| May 17, 2024 Filed May 17, 2024 23:48 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 47,250 | $3.33 | $157,252.73 |
DisclosureSEC source: 0001493152-24-020507 · ownership.xml · nonDerivative · entry 1 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 2,333,044 F3 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.01-$3.60 inclusive. The reporting person undertakes to provide,upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| May 10, 2024 Filed May 10, 2024 22:57 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 151,700 | $3.11 | $472,424.14 |
DisclosureSEC source: 0001493152-24-018723 · ownership.xml · nonDerivative · entry 2 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 2,380,294 F3 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.00-$3.20 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| May 09, 2024 Filed May 10, 2024 22:57 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 30,600 | $3.09 | $94,526.46 |
DisclosureSEC source: 0001493152-24-018723 · ownership.xml · nonDerivative · entry 1 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 2,531,994 F2 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.05-$3.15 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| April 25, 2024 Filed Apr 25, 2024 21:19 UTC | HARROW, INC. HROW · Entity 4740 | PurchaseCommon Stock, par value $0.001 per share | 20,000 | $9.97 | $199,400.00 |
DisclosureSEC source: 0001493152-24-015983 · ownership.xml · nonDerivative · entry 1 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 3,815,000 F2 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.91-$10.01 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| April 24, 2024 Filed Apr 24, 2024 20:40 UTC | HARROW, INC. HROW · Entity 4740 | PurchaseCommon Stock, par value $0.001 per share | 8,285 | $10.15 | $84,092.75 |
DisclosureSEC source: 0001493152-24-015806 · ownership.xml · nonDerivative · entry 2 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 3,795,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.09-$10.19 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| April 23, 2024 Filed Apr 24, 2024 20:40 UTC | HARROW, INC. HROW · Entity 4740 | PurchaseCommon Stock, par value $0.001 per share | 11,715 | $10.29 | $120,547.35 |
DisclosureSEC source: 0001493152-24-015806 · ownership.xml · nonDerivative · entry 1 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 3,786,715 F2 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.28-$10.2942 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| April 19, 2024 Filed Apr 19, 2024 22:24 UTC | HARROW, INC. HROW · Entity 4740 | PurchaseCommon Stock, par value $0.001 per share | 29,400 | $10.56 | $310,390.50 |
DisclosureSEC source: 0001493152-24-015410 · ownership.xml · nonDerivative · entry 1 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 3,775,000 F2 · price: The common stock was purchased by the reporting person in open market transactions on the transaction date. The range of purchase prices per share on the transaction date was $10.34-10.8256. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| March 28, 2024 Filed Mar 28, 2024 22:07 UTC | HARROW, INC. HROW · Entity 4740 | PurchaseCommon Stock, par value $0.001 per share | 50,000 | $12.82 | $641,000.00 |
DisclosureSEC source: 0001493152-24-011815 · ownership.xml · nonDerivative · entry 1 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 3,745,600 F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| March 20, 2024 Filed Mar 22, 2024 15:52 UTC | HARROW, INC. HROW · Entity 4740 | PurchaseCommon Stock, par value $0.001 per share | 50,600 | $9.65 | $488,290.00 |
DisclosureSEC source: 0001493152-24-010936 · ownership.xml · nonDerivative · entry 1 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 3,695,600 F2 · price: The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume-weighted average purchase price of $9.6536. The range of purchase prices per share on the transaction date was $9.48-9.74. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 21:05 UTC | HARROW, INC. HROW · Entity 4740 | PurchaseCommon Stock, par value $0.001 per share | 25,000 | $8.03 | $200,735.00 |
DisclosureSEC source: 0001493152-23-041661 · ownership.xml · nonDerivative · entry 1 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 3,645,000 F2 · price: The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume-weighted average purchase price of $8.0294. The range of purchase prices per share on the transaction date was $7.91-8.13. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| November 10, 2023 Filed Nov 14, 2023 16:05 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | SaleCommon Stock, par value $0.001 per share | 440,000 | $0.29 | $129,448.00 |
DisclosureSEC source: 0001493152-23-041038 · ownership.xml · nonDerivative · entry 2 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Managed account Disclosed balance after: 0 F3 · shares: This transaction was executed in multiple trades at prices ranging from $0.21 to $0.375; the price reported above reflects the weighted average purchase price. The reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased. F2 · ownership.nature: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to own the securities owned directly by the Managed Account beneficially. Read SEC document |
| November 10, 2023 Filed Nov 14, 2023 16:05 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | SaleCommon Stock, par value $0.001 per share | 4,324,008 | $0.29 | $1,272,123.15 |
DisclosureSEC source: 0001493152-23-041038 · ownership.xml · nonDerivative · entry 1 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 0 F3 · shares: This transaction was executed in multiple trades at prices ranging from $0.21 to $0.375; the price reported above reflects the weighted average purchase price. The reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased. F3 · price: This transaction was executed in multiple trades at prices ranging from $0.21 to $0.375; the price reported above reflects the weighted average purchase price. The reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (The "Fund"). As the investment manager of the Fund. Read SEC document |
| September 20, 2023 Filed Sep 20, 2023 22:39 UTC | HARROW, INC. HROW · Entity 4740 | PurchaseCommon Stock, par value $0.001 per share | 5,983 | $14.49 | $86,710.42 |
DisclosureSEC source: 0001493152-23-033247 · ownership.xml · nonDerivative · entry 2 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 3,620,000 F3 · price: The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume-weighted average purchase price of $14.4928. The range of purchase prices per share on the transaction date was $14.22 to $14.67. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 22:39 UTC | HARROW, INC. HROW · Entity 4740 | PurchaseCommon Stock, par value $0.001 per share | 14,017 | $14.65 | $205,365.87 |
DisclosureSEC source: 0001493152-23-033247 · ownership.xml · nonDerivative · entry 1 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 3,614,017 F2 · price: The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume-weighted average purchase price of $14.6512. The range of purchase prices per share on the transaction date was $14.59 to $14.73. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| March 09, 2023 Filed Mar 13, 2023 16:05 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock, par value $0.001 per share | 174,508 | $1.38 | $240,821.04 |
DisclosureSEC source: 0001493152-23-007400 · ownership.xml · nonDerivative · entry 1 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 4,324,508 F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| December 30, 2022 Filed Dec 30, 2022 23:00 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 2,300 | $2.71 | $6,235.53 |
DisclosureSEC source: 0001493152-22-037191 · ownership.xml · nonDerivative · entry 2 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Managed Account Disclosed balance after: 130,000 F3 · price: The prices reported above reflects the weighted average purchase price. These transactions were executed in multiple trades between $2.69 and $2.75. The reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased. F2 · ownership.nature: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. Read SEC document |
| December 30, 2022 Filed Dec 30, 2022 23:00 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | SaleCommon Stock, par value $0.001 per share | 13,173 | $2.71 | $35,713.32 |
DisclosureSEC source: 0001493152-22-037191 · ownership.xml · nonDerivative · entry 1 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 2,562,594 F3 · price: The prices reported above reflects the weighted average purchase price. These transactions were executed in multiple trades between $2.69 and $2.75. The reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased. F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| December 14, 2022 Filed Dec 14, 2022 21:05 UTC | HARROW, INC. HROW · Entity 4740 | PurchaseCommon Stock, par value $0.001 per share | 16,183 | $10.52 | $170,245.16 |
DisclosureSEC source: 0001493152-22-035435 · ownership.xml · nonDerivative · entry 2 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Managed Account Disclosed balance after: 175,000 F2 · ownership.nature: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. Read SEC document |
| December 14, 2022 Filed Dec 14, 2022 21:05 UTC | HARROW, INC. HROW · Entity 4740 | PurchaseCommon Stock, par value $0.001 per share | 415,000 | $10.52 | $4,365,800.00 |
DisclosureSEC source: 0001493152-22-035435 · ownership.xml · nonDerivative · entry 1 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Opaleye, L.P. Disclosed balance after: 3,600,000 F1 · ownership.nature: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 17:03 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock, par value $0.001 per share | 27,500 | $1.24 | $34,050.50 |
DisclosureSEC source: 0001493152-22-035779 · ownership.xml · nonDerivative · entry 2 Opaleye Management Inc. · CIK 0001595855 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Managed Account. Disclosed balance after: 440,000 F3 · price: The prices reported above reflects the weighted average purchase price. These transactions were executed in multiple trades between $1.14 and $1.34. The reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased. F2 · ownership.nature: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.